Home
LENZ
LENZ News

Latest LENZ Therapeutics Inc. Common Stock (LENZ) News on December 22, 2024

We're Hopeful That LENZ Therapeutics (NASDAQ:LENZ) Will Use Its Cash Wisely

Simply Wall St.

21 days ago

We're Hopeful That LENZ Therapeutics (NASDAQ:LENZ) Will Use Its Cash Wisely

LENZ Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

a month ago

LENZ Therapeutics to Participate in Upcoming Investor Conferences

LENZ Therapeutics Reports Third Quarter 2024 Financial Results

GlobeNewswire

2 months ago

LENZ Therapeutics Reports Third Quarter 2024 Financial Results

LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024

GlobeNewswire

2 months ago

LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024

CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100

GlobeNewswire

2 months ago

CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100

Lenz Therapeutics announces FDA acceptance of NDA for LNZ100

TipRanks

2 months ago

Lenz Therapeutics announces FDA acceptance of NDA for LNZ100

GlobeNewswire

2 months ago

LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia

GlobeNewswire

3 months ago

LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences

LENZ Therapeutics Insiders Up US$178k On US$551.1k Investment

Simply Wall St.

3 months ago

LENZ Therapeutics Insiders Up US$178k On US$551.1k Investment

GlobeNewswire

4 months ago

LENZ Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

4 months ago

LENZ Therapeutics Reports Second Quarter 2024 Financial Results

GlobeNewswire

4 months ago

LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia

GlobeNewswire

4 months ago

LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

GlobeNewswire

5 months ago

LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital

We Think LENZ Therapeutics (NASDAQ:LENZ) Can Afford To Drive Business Growth

Simply Wall St.

6 months ago

We Think LENZ Therapeutics (NASDAQ:LENZ) Can Afford To Drive Business Growth

GlobeNewswire

6 months ago

LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024

GlobeNewswire

7 months ago

LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire

7 months ago

LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire

8 months ago

LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials

Business Wire

9 months ago

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials

Business Wire

9 months ago

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials

Share on Social Networks: